For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total collaboration revenue | 0 | - | ||
| Research and development expense | 418,778 | 396,440 | ||
| General and administration | 136,564 | 105,438 | ||
| Total operating expenses | 555,342 | 501,878 | ||
| Gain from divestiture of small molecule programs | 0 | 14,537 | ||
| Loss from operations | -555,342 | -487,341 | ||
| Interest and other income, net | 42,904 | 64,636 | ||
| Loss before income taxes | -512,438 | -422,705 | ||
| Income tax expense | 102 | 68 | ||
| Net loss | -512,540 | -422,773 | ||
| Net unrealized gain (loss) on marketable securities, net of tax | -1,338 | 1,377 | ||
| Comprehensive loss | -513,878 | -421,396 | ||
| Basic EPS | -2.97 | -2.57 | ||
| Diluted EPS | -2.97 | -2.57 | ||
| Basic Average Shares | 172,649,097 | 164,473,772 | ||
| Diluted Average Shares | 172,649,097 | 164,473,772 | ||
Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI)